Trust Co. of Vermont Makes New Investment in Pfizer Inc. $PFE

Trust Co. of Vermont acquired a new stake in Pfizer Inc. (NYSE:PFE) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 158,728 shares of the biopharmaceutical company’s stock, valued at approximately $3,822,000.

A number of other hedge funds also recently made changes to their positions in PFE. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Pfizer by 8.5% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 14,060,742 shares of the biopharmaceutical company’s stock worth $338,583,000 after purchasing an additional 1,098,549 shares in the last quarter. Plato Investment Management Ltd grew its holdings in Pfizer by 41.5% during the 2nd quarter. Plato Investment Management Ltd now owns 225,254 shares of the biopharmaceutical company’s stock valued at $5,392,000 after purchasing an additional 66,017 shares in the last quarter. Cura Wealth Advisors LLC grew its holdings in Pfizer by 5.8% during the 2nd quarter. Cura Wealth Advisors LLC now owns 21,140 shares of the biopharmaceutical company’s stock valued at $509,000 after purchasing an additional 1,167 shares in the last quarter. Simplicity Wealth LLC increased its stake in Pfizer by 144.2% during the 2nd quarter. Simplicity Wealth LLC now owns 109,120 shares of the biopharmaceutical company’s stock worth $2,628,000 after buying an additional 64,440 shares during the period. Finally, Wealth Effects LLC lifted its holdings in Pfizer by 2.6% in the 2nd quarter. Wealth Effects LLC now owns 78,083 shares of the biopharmaceutical company’s stock worth $1,880,000 after buying an additional 2,008 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.8%

NYSE:PFE opened at $28.00 on Friday. The company has a market capitalization of $159.59 billion, a price-to-earnings ratio of 36.84 and a beta of 0.34. Pfizer Inc. has a one year low of $23.58 and a one year high of $28.75. The stock has a 50-day simple moving average of $25.30 and a 200 day simple moving average of $26.25. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter in the prior year, the firm posted $0.78 earnings per share. Pfizer’s revenue for the quarter was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 6.1%. Pfizer’s dividend payout ratio (DPR) is 226.32%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer completed a Phase 1/2 study of PF-07868489, an experimental treatment for pulmonary arterial hypertension. The milestone supports early-stage pipeline progress, though additional clinical testing will be needed before any potential commercialization. Pfizer’s PF-07868489 PAH Study Reaches Completion
• Positive Sentiment: Several additional clinical updates highlighted progress across Pfizer’s development portfolio: completion of a Phase 1 atirmociclib study, completion of a drug-interaction study for PF-07248144, and a new Phase 1 liver study for atirmociclib. These milestones may reinforce confidence in Pfizer’s ability to replenish revenue as older products face competition. Atirmociclib Study Update PF-07248144 Study Update
• Positive Sentiment: Pfizer is also expanding real-world evidence efforts for prostate cancer therapies, Ibrance in advanced breast cancer, and a migraine treatment study in India. These studies could support broader use and strengthen commercial evidence for existing medicines. Pfizer Real-World Prostate Cancer Study
• Positive Sentiment: Investor-oriented coverage remains constructive, citing Pfizer’s roughly 19% year-to-date gain, attractive dividend yield, and reported hedge-fund buying. The stock’s move toward its 52-week high suggests improving sentiment. Hedge Funds Buying Pfizer
• Neutral Sentiment: Unusually large options activity may increase short-term trading interest, but it does not establish a clear fundamental direction for PFE. Pfizer Options Trading
• Negative Sentiment: Coverage of settlements involving thousands of Depo-Provera lawsuits raises concerns about potential legal costs and ongoing liability. Analysts also continue to weigh whether new drugs and acquisitions can offset revenue losses from expiring patents. Pfizer Legal Claims

Analyst Ratings Changes

A number of research firms have weighed in on PFE. Guggenheim decreased their price objective on shares of Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a research report on Friday, August 7th. Bank of America cut their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. JPMorgan Chase & Co. reduced their price target on Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a report on Wednesday, July 8th. Cantor Fitzgerald restated a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research note on Monday, July 6th. Finally, Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $28.28.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.